Comparison of clinicopathological features and long-term prognosis between mixed predominantly differentiated-type and pure differentiated-type early gastric cancer.
Adult
Aged
Aged, 80 and over
Cell Differentiation
Endoscopic Mucosal Resection
Female
Follow-Up Studies
Gastrectomy
Gastric Mucosa
/ diagnostic imaging
Gastroscopy
Humans
Kaplan-Meier Estimate
Lymphatic Metastasis
/ pathology
Male
Middle Aged
Neoplasm Invasiveness
/ pathology
Neoplasm Recurrence, Local
/ epidemiology
Neoplasm Staging
Prognosis
Retrospective Studies
Risk Factors
Stomach Neoplasms
/ diagnosis
Survival Rate
Time Factors
Treatment Outcome
Adenocarcinoma
Gastric cancer
Histology
Prognosis
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
06 Mar 2021
06 Mar 2021
Historique:
received:
20
07
2020
accepted:
24
02
2021
entrez:
7
3
2021
pubmed:
8
3
2021
medline:
4
5
2021
Statut:
epublish
Résumé
Recent studies have shown that mixed predominantly differentiated-type (MD) early gastric cancer (EGC) might have more malignant potential than pure differentiated-type (PD) EGC. However, no study has analyzed all differentiated-type EGC cases treated endoscopically and surgically. This study aimed to compare the differences in clinicopathological features and long-term prognosis between MD- and PD-EGC. We evaluated all patients with differentiated-type EGCs who were treated endoscopically and surgically in our hospital between January 2010 and October 2014. The clinicopathological features and long-term prognosis of MD-EGC were compared with those of PD-EGC. A total of 459 patients with 459 lesions were evaluated in this study; of them, 409 (89.1%) and 50 (10.9%) were classified into the PD and MD groups, respectively. Submucosal invasion was found in 96 (23.5%) patients of the PD group and in 33 (66.0%) patients of the MD group (p < 0.01). The rates of positive lymphatic and vascular invasion and ulceration were significantly higher in the MD group than in the PD group (p < 0.01). The proportion of patients with lymph node metastasis was also significantly higher in the MD group than in the PD group (5 (10%) vs 6 (1.5%), p < 0.01). The 5-year overall and EGC-specific survival rates in the PD group were 88.3 and 99.5%, respectively, while they were 94.0 and 98.0% in the MD group, respectively. MD-EGC has more malignant potential than PD-EGC. However, the long-term prognosis of MD-EGC is good and is not significantly different from that of PD-EGC when treated appropriately.
Sections du résumé
BACKGROUND
BACKGROUND
Recent studies have shown that mixed predominantly differentiated-type (MD) early gastric cancer (EGC) might have more malignant potential than pure differentiated-type (PD) EGC. However, no study has analyzed all differentiated-type EGC cases treated endoscopically and surgically. This study aimed to compare the differences in clinicopathological features and long-term prognosis between MD- and PD-EGC.
METHODS
METHODS
We evaluated all patients with differentiated-type EGCs who were treated endoscopically and surgically in our hospital between January 2010 and October 2014. The clinicopathological features and long-term prognosis of MD-EGC were compared with those of PD-EGC.
RESULTS
RESULTS
A total of 459 patients with 459 lesions were evaluated in this study; of them, 409 (89.1%) and 50 (10.9%) were classified into the PD and MD groups, respectively. Submucosal invasion was found in 96 (23.5%) patients of the PD group and in 33 (66.0%) patients of the MD group (p < 0.01). The rates of positive lymphatic and vascular invasion and ulceration were significantly higher in the MD group than in the PD group (p < 0.01). The proportion of patients with lymph node metastasis was also significantly higher in the MD group than in the PD group (5 (10%) vs 6 (1.5%), p < 0.01). The 5-year overall and EGC-specific survival rates in the PD group were 88.3 and 99.5%, respectively, while they were 94.0 and 98.0% in the MD group, respectively.
CONCLUSIONS
CONCLUSIONS
MD-EGC has more malignant potential than PD-EGC. However, the long-term prognosis of MD-EGC is good and is not significantly different from that of PD-EGC when treated appropriately.
Identifiants
pubmed: 33676442
doi: 10.1186/s12885-021-07962-x
pii: 10.1186/s12885-021-07962-x
pmc: PMC7937263
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
235Références
Jpn J Clin Oncol. 2001 Oct;31(10):495-9
pubmed: 11696619
J Gastroenterol. 2015 Apr;50(4):424-34
pubmed: 25142800
J Surg Res. 2019 Apr;236:271-277
pubmed: 30694766
Gastric Cancer. 2015 Jul;18(3):618-26
pubmed: 24801199
Dig Endosc. 2018 Sep;30(5):624-632
pubmed: 29570860
Surg Endosc. 2015 Jul;29(7):1787-94
pubmed: 25277481
Gastric Cancer. 2012 Apr;15(2):221-5
pubmed: 22083418
Br J Surg. 2001 Mar;88(3):444-9
pubmed: 11260114
Gastric Cancer. 2013 Oct;16(4):531-6
pubmed: 23192620
Ann Surg Oncol. 2015;22(6):1813-9
pubmed: 25344305
Gastric Cancer. 2017 Mar;20(Suppl 1):45-52
pubmed: 27807641
Gastric Cancer. 2008;11(1):47-52
pubmed: 18373177
World J Gastroenterol. 2016 Apr 21;22(15):4020-6
pubmed: 27099445
Endosc Int Open. 2019 Jun;7(6):E841-E845
pubmed: 31198850
Gastric Cancer. 2018 Jul;21(4):689-695
pubmed: 29236187
Gastric Cancer. 2019 Mar;22(2):363-368
pubmed: 30039320
Gastric Cancer. 2017 Jan;20(1):1-19
pubmed: 27342689
Gastric Cancer. 2011 Jun;14(2):101-12
pubmed: 21573743
Br J Surg. 2002 Aug;89(8):1035-42
pubmed: 12153632
J Gastroenterol. 2016 Oct;51(10):961-70
pubmed: 26884381
Gut. 2001 Feb;48(2):225-9
pubmed: 11156645
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Ann Surg Oncol. 2016 Dec;23(Suppl 5):784-791
pubmed: 27613552
Gastric Cancer. 2006;9(4):262-70
pubmed: 17235627
Tumour Biol. 2016 Jan;37(1):709-14
pubmed: 26242270
Gastric Cancer. 2018 Jan;21(1):144-154
pubmed: 28417260